FRACTURA DE CADERA. Anciano afecto de <strong>fractura</strong> de <strong>cadera</strong> 144. Devine A, Dick IM, Heal SJ, Criddle RA, Prince RL. A 4-year follow-up of study of the effects of calcium supplementation on bone density in elderly postmenopausal women. Osteoporosis Int. 1997;7:23-8. 145. Reid IR, Ames RW, Evans MC, Gamble GD, Sharp SJ. Long-term effects of calcium supplementation on bone loss and fractures in postmenopausal women: a randomised controlled trial. Am J Med. 1995;98:331-5. 146. Bischoff-Ferrari HA, Willett WC, Wong JB, Giovannucci E, Dietrich T, Dawson-Hughes B. Fracture prevention with vitamin D supplementation: a meta-analysis of randomized controlled trials. JAMA. 2005;293:2257-64. 147. Bischoff-Ferrari HA, Dawson-Hughes B, Willett WC, Staehelin HB, Bazemore MG, Zee RY, et al. Effect of vitamin D on falls: a meta-analysis. JAMA. 2004;291:1999-2006. 148. Guillespie WJ, Henry DA, O’Connell DL, Robertson J. Vitamin D and vitamin D analogues for preventing fractures associated with involutional and postmenopausal osteoporosis. Cochrane Database Syst Rev. 2000;3:1-36. 149. Chapuy MC, Arlot ME, Dubouef F, Brun J, Crouzet B, Arnaud S, et al. Vitamin D3 and calcium to prevent hip fractures in the elderly women. N Engl J Med. 1992;327:1637-42. 150. Dawson-Hughes B, Harris SS, Krall EA, Dallal GE. Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. N Engl J Med. 1997;337:670-6. 151. Gillespie WJ, Henry DA, O’Connell DL, Robertson J. Vitamin D and Vitamin D analogues for preventing fractures associated with involutional and postmenopausal osteoporosis (Cochrane Review). En: The Cochrane Library. Issue 1. Oxford: Update Software; 1999. 152. Register JY, Seaman E, De Vernejoul S, Adami J, Comspton C, Phenekos JP, et al. Strontium ranelate reduces the risk of non vertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) Study. J Clin Endocrinol Metab. 2005;90:2816-22. 153. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Mevitt MC, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet. 1996;348;1535-41. 154. Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett-Connor E, Musliner TA, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA. 1998;280:2077-82. 155. Black DM, Thompson DE, Bauer DC, Ensrud K, Musliner T, Hochberg MC, et al. Fracture risk reduction with alendronato in women with osteoporosis: the fracture intervention trial. FIT Research Group. J Clin Endocrinol Metab. 2000;85:4118-24. 156. McClung MR, Geusens P, Miller PD, Zippel H, Bensen WG, Roux C, et al. Effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med. 2001;344:333-40. 157. Boonen S, McClung MR, Eastell R, Fuleihan GE, Barton IP, Delmas P. Safety and efficacy of risedronate in reducing fracture risk in osteoporotic women aged 80 and older: implications for the use of antiresortive agents in the old and oldest old. JAGS. 2004:52:1832-9. 135
Guía de buena práctica clínica en Geriatría. FRACTURA DE CADERA 158. Cranney A, Welch V, Adachi JD, et al. Etidronato for treating and preventing postmenopausal osteoporosis (Cochrane Review). En: Cochrane Llibrary. Issue 2. Chinchester: John Wiley & Sons; 2004. 159. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, et al. Effect of parathyroid hormona (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001;344:1434-41. 160. Kenny AM. Tratamiento hormonal sustitutivo. En: GRS Geriatric Review Syllabus (ed. esp.). 5.ª ed. American Geriatric Society. Barcelona: Medical Trends; 2003. p. 333-8. 136
Change language